Epidemiology of MPN: What Do We Know?

Current Hematologic Malignancy Reports

Volumn 9, Issue 4, 2014, Pages 340-349

  Anderson, L A ^a   McMullin, M F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Benzene; Body mass index; Diet; Epidemiology; Myeloproliferative neoplasms; Survival

Indexed keywords

HUMAN; MORTALITY; MYELOPROLIFERATIVE DISORDERS; SURVIVAL;

HUMANS; MYELOPROLIFERATIVE DISORDERS; SURVIVAL ANALYSIS;

EID: 84936758584     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0228-z     Document Type: Review

References (105)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2. James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
3. Mc Lornan DP, Percy MJ, Jones AV, Cross NCP, Mc Mullin MF. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica. 2005;90:1696–7.
4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.
5. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–6.
6. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141–9.
7. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.
8. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301.
9. Klampfl T, Gisslinger H, Harutyunyan AS, Them NC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405. In this issue of the journal CALR, mutations were described by two groups for the first time in patients with myeloproliferative neoplasms who were negative for the previously discovered acquired mutations. Thus, a new acquired clone was demonstrated in these patients.
10. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol. 2014;89:450.
11. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27:1870–3.
12. Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13:180–8.
13. Broccia G, Deplano W, Dessalvi P, et al. Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence. Hematol Oncol. 2004;22:91–109.
14. Johansson P, Kutti J, Andréasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med. 2004;256:161–5.
15. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–7. This paper analyses all published information on incidence and prevalence of myeloproliferative neoplasms and derives composite figures for each disorder from the information.
16. Nennecke A, Wienecke A, Kraywinkel K. Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:93–102.
17. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411–7.
18. Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009;9:252.
19. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.
20. Radivoyevitch T, Jankovic GM, Tiu RV, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014;53:55–63.
21. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118:3123–7.
22. Kurita S. Epidemiological studies of polycythemia vera in Japan (author’s transl). Nihon Ketsueki Gakkai Zasshi. 1974;37:793–5.
23. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma. 1992;7:251–5.
24. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52.
25. Phekoo KJ, Richards MA, Møller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91:1400–4.
26. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment. Leuk Res. 2007;31:737–40.
27. Modan B. An epidemiological study of polycythemia vera. Blood. 1965;26:657–67.
28. Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65:132–9.
29. Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases. Med J Aust. 1976;1:523–5.
30. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–97. This is a systematic study of literature and databases to elucidate information on incidence and prevalence of myeloproliferative neoplasms in Europe.
31. Bittencourt RI, Vassallo J, Chauffaille ML, et al. Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2012;34:140–9.
32. Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haemat. 2014;166:521–8.
33. Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res. 2013;3:159–72.
34. Maynadié M, De Angelis R, Marcos-Gragera R, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230–8.
35. Sant M, Minicozzi P, Mounier M, et al. Remarkable survival improvements for haematological malignancies highlighted by the EUROCARE population based registries from late nineties to 2008. Lancet Oncol 2014; (in press).
36. Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119:2620–9.
37. Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open. 2014;4:e004266.
38. Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US. Acta Oncol. 2013;52:837–41.
39. Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood. 2009;113:3428–34.
40. Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30:2995–3001.
41. Cherry M, Cardenas-Turanzas M, Pham H, et al. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res. 2013;37:1472–6.
42. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.
43. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251–4.
44. Montanaro M, Latagliata R, Cedrone M, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1144 patients. Am J Hematol. 2014;89:542–6.
45. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197–201.
46. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–6.
47. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30:2981–7.
48. Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol. 2012;30:1087–94.
49. Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27:2084–6.
50. Helbig G, Wieczorkiewicz A, Woźniczka K, et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol. 2012;29:2379–84.
51. Martínez-Trillos A, Maffioli M, Colomer D, et al. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Ann Hematol. 2014;93:797–802.
52. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9.
53. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28:1494–500.
54. Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 2014;31:869.
55. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121:4832–7.
56. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98:1865–71.
57. Wang JS, Ho CH, Lin CK. Chronic neutrophilic leukemia—report of a case and review of the literature. Zhonghua Yi Xue Za Zhi (Taipei). 1990;46:109–12.
58. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313–7.
59. Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol. 2002;116:10–8.
60. Damaj G, Joris M, Chandesris O, et al. ASXL1 and not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE. 2014;9:e85362.
61. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514521.
62. Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 2013;108:2390–8. A cohort of over a million women in the UK were followed for 10 years providing a wealth of data. Incident cancer was ascertained. This paper looks at haematological malignancy and body size and height and what associations occur.
63. Kabat GC, Wu JW, Moore SC, et al. Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. 2013;22:848–54.
64. Saberi Hosnijeh F, Romieu I, et al. Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Cancer Causes Control. 2013;24:427–38. A study investigating the association between cancer and nutrition following patients in 10 European countries. There were 671 patients with leukaemia followed for a median of 11.5 years and the relationships with anthropomorphic characteristics are studied in the paper.
65. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122:1418–21.
66. Engeland A, Tretli S, Hansen S, Bjørge T. Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol. 2007;165:44–52.
67. Kasim K, Levallois P, Abdous B, Auger P, Johnson KC. Lifestyle factors and the risk of adult leukemia in Canada. Cancer Causes Control. 2005;16:489–500.
68. Strom SS, Yamamura Y, Kantarijian HM, Cortes-Franco JE. Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2009;18:1501–6.
69. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women’s Health Study cohort. Int J Cancer. 2014;134:1741–50.
70. Kasim K, Johnson KC, Levallois P, Abdous B, Auger P. Recreational physical activity and the risk of adult leukemia in Canada. Cancer Causes Control. 2009;20:1377–86.
71. Saberi Hosnijeh F, Peeters P, Romieu I, et al. Dietary intakes and risk of lymphoid and myeloid leukemia in the European prospective investigation into cancer and nutrition (EPIC). Nutr Cancer. 2014;66:14–28. This paper looks in detail at a large number of dietary factors in this very extensively investigated cohort of European patients and explores any links to the haematological malignancy.
72. Musselman JRB, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 2013;37:410–6.
73. Richardson DB, Terschüren C, Pohlabeln H, Jöckel K-H, Hoffmann W. Temporal patterns of association between cigarette smoking and leukemia risk. Cancer Causes Control. 2008;19:43–50.
74. Björk J, Albin M, Welinder H, et al. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med. 2001;58:722–7.
75. Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK million women study. Br J Cancer. 2012;107:879–87. Looking at degrees of alcohol and tobacco consumption and relationship to haematological malignancy in this 1.3 million group of women, the size and extent of this vast study provides useful evidence.
76. Mele A, Visani G, Pulsoni A, Monarca B, Castelli G, Stazi MA, et al. Risk factors for essential thrombocythemia: a case-control study. Italian leukemia study group. Cancer. 1996;77:2157–61.
77. Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, et al. Alcohol consumption and risk of leukemia: a multicenter case-control study. Leuk Res. 2007;31:379–86.
78. Shadman M, White E, De Roos AJ, Walter RB. Associations between allergies and risk of hematologic malignancies: results from the VITamins And Lifestyle cohort study. Am J Hematol. 2013;88:1050–4.
79. Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev. 2010;19:1229–37.
80. Shebl FM, Warren JL, Eggers PW, Engels EA. Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study. BMC Nephrol. 2012;13:65.
81. Titmarsh GJ, McMullin MF, McShane CM, Clarke M, Engels EA, Anderson LA. Community-acquired infections and their association with myeloid malignancies. Cancer Epidemiol. 2013;38:56–61. The SEER database has extensive information on medical conditions in a very large group. This paper interrogates the database to investigate for infections and associations with myeloid malignancy prior to diagnosis. A number of interesting associations are discovered.
82. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822–8.
83. Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 2008;17:3069–75.
84. Gentile G, Mele A, Monarco B, et al. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. Ital Leuk Study Group Cancer Epidemiol Biomark Prev. 1996;5:227–30.
85. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF. Prior medical conditions and the risk of adult leukemia in Shanghai, People’s Republic of China. Cancer Causes Control. 1993;4:361–8.
86. Johnson KJ, Blair CM, Fink JM, et al. Medical conditions and risk of adult myeloid leukemia. Cancer Causes Control. 2012;23:1083–9.
87. Howard RA, Gilbert ES, Chen BE, et al. Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat. 2007;105:359–68.
88. Pizzolito S, Barbone F, Rizzi C, Scott A, Piemonte M, Beltrami C. Parathyroid adenomas and malignant neoplasms: coincidence or etiological association? Adv Clin Path. 1997;1:275–80.
89. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Envir Health. 2010;9:31.
90. Vlaanderen J, Lan Q, Kromhout H, Rothman N, Vermeulen R. Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med. 2012;55:779–85.
91. Glass DC, Schnatter AR, Tang G, Irons RD, Rushton L. Risk of myeloproliferative disease and chronic myeloid leukaemia following exposure to low-level benzene in a nested case-control study of petroleum workers. Occup Environ Med. 2014;71:266–74.
92. Terreros M. Exposure to occupational and environmental risk factors in hematologic disorders. Neoplasia. 1997;14:133–6.
93. Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012;87:175–82. In this study, all the published literature on the aetiology of myeloproliferative neoplasms is analyzed and findings are summarised and presented.
94. Luckhaupt SE, Deapen D, Cress R, Schumacher P, Shen R, Calvert GM. Leukemia among male construction workers in California, 1988-2007. Leuk Lymphoma. 2012;53:2228–36.
95. Giles GG, Lickiss JN, Baikie MJ, Lowenthal RM, Panton J. Myeloproliferative and lymphoproliferative disorders in Tasmania, 1972-80: occupational and familial aspects. J Natl Cancer Inst. 1984;72:1233–40.
96. Van Maele-Fabry G, Duhayon S, Lison D. A systematic review of myeloid leukemias and occupational pesticide exposure. Cancer Causes Control. 2007;18:457–78.
97. Falcetta R, Sacerdote C, Bazzan M, et al. Occupational and environmental risk factors for essential thrombocythemia: a case-control study. G Ital Med Lav Ergon. 2014;25:9–12.
98. Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol. 1991;38:147–9.
99. Sorahan T. Magnetic fields and leukaemia risks in UK electricity supply workers. Occup Med (Lond). 2014;64:157–65.
100. Feychting M, Ahlbom A. Magnetic fields, leukemia, and central nervous system tumors in Swedish adults residing near high-voltage power lines. Epidemiology. 1994;5:501–9.
101. Feychting M, Forssén U, Floderus B. Occupational and residential magnetic field exposure and leukemia and central nervous system tumors. Epidemiology. 1997;8:384–9.
102. Hsu W-L, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res. 2013;179:361–82.
103. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther. 1998;40:159–65.
104. Merk K, Mattsson B, Mattsson A, Holm G, Gullbring B, Björkholm M. The incidence of cancer among blood donors. Int J Epidemiol. 1990;19:505–9.
105. Magnussen K, Hasselbalch HC, Ullum H, Bjerrum OW. Characterization of blood donors with high haemoglobin concentration. Vox Sang. 2013;104:110–4.